Shapiro R, Jordan M L, Scantlebury V P, Fung J J, Jensen C, Vivas C, McCauley J, Irish W D, Mitchell S, Demetris A J
Department of Surgery, University of Pittsburgh Health Science Center, Pennsylvania.
Transplant Proc. 1993 Feb;25(1 Pt 1):669-72.
FK 506 was used as a primary immunosuppressive agent in 125 cases of renal transplantation in a randomized trial comparing FK 506/prednisone with FK 506/azathioprine/prednisone. With a mean follow-up of 5.5 +/- 2.5 months, there has been a 6-month actuarial patient survival of 99% and graft survival of 88%. There is no difference thus far between the two-drug and three-drug groups, although there may be less rejection and diabetes in the three-drug group. These results suggest that FK 506 is a useful immunosuppressive agent in kidney transplantation.
在一项将FK 506/泼尼松与FK 506/硫唑嘌呤/泼尼松进行对比的随机试验中，FK 506被用作125例肾移植患者的主要免疫抑制剂。平均随访时间为5.5±2.5个月，6个月时患者实际生存率为99%，移植物生存率为88%。到目前为止，两药组和三药组之间没有差异，尽管三药组的排斥反应和糖尿病可能较少。这些结果表明，FK 506在肾移植中是一种有用的免疫抑制剂。
